Reported 12 months ago
Income-oriented investors are drawn to Altria Group for its high dividend yield and consistent dividend growth, even though revenue has been declining. However, with recent FDA approval for NJOY's menthol e-cigarettes, Altria's revenue growth prospects are improving. Despite facing competition from illicit Chinese vaping products, NJOY's FDA-authorized flavored vaping products put it in a strong market position. Altria's focus on expanding distribution and potential revenue growth with NJOY make it an attractive option for investors seeking dividend income and growth potential.
Source: YAHOO